Trials / Completed
CompletedNCT02877927
Oral Omadacycline vs. Oral Linezolid for the Treatment of ABSSSI
A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Oral Omadacycline to Oral Linezolid for Treating Adult Subjects With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 735 (actual)
- Sponsor
- Paratek Pharmaceuticals Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of omadacycline as compared to linezolid in the treatment of adults with acute bacterial skin and skin structure infections.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Omadacycline | po tablets |
| DRUG | Linezolid | po tablets |
Timeline
- Start date
- 2016-08-01
- Primary completion
- 2017-05-26
- Completion
- 2017-06-06
- First posted
- 2016-08-24
- Last updated
- 2018-11-30
- Results posted
- 2018-11-30
Locations
50 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02877927. Inclusion in this directory is not an endorsement.